Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab
about
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe challenges and the promise of molecular targeted therapy in malignant gliomas.Profile of nimotuzumab in the treatment of high-grade gliomaCombined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.Trends in Malignant Glioma Monoclonal Antibody Therapy.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26993238-A8E03FC9-8B4C-49F3-87AF-DF6A8B7D16FAQ35214534-6352A853-273C-4D58-A590-71A061F1615FQ35491503-C8DE6B32-EFB3-4552-8BA6-5BA52F6EEBA3Q35534349-A367A8E4-32E0-400D-B4E7-966E132368EFQ36962460-DA92231D-A76C-4A54-969A-EA53B494CEACQ37269328-F7D23685-B866-4B16-8344-4632AFEC1ED0Q38127413-9E735198-FF77-4AEE-808E-C5A9D77BC924Q49359610-013FC380-9C0C-4745-9C4F-339FA6E4030BQ52641348-0188D859-7E41-41D7-8126-7B53F53F7243Q54942652-17BAEE15-9C82-4BB1-AFA9-C93927A8B06DQ56932681-12B0BBAC-C54A-4A2B-A59D-BB3274884EF7
P2860
Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@ast
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@en
type
label
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@ast
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@en
prefLabel
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@ast
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@en
P2093
P2860
P356
P1476
Nimotuzumab prolongs survival ...... py with or without nimotuzumab
@en
P2093
Chaojun Duan
Jidong Hong
Meizuo Zhong
Wuzhong Jiang
Yuping Liao
Yuping Peng
P2860
P304
P356
10.3892/ETM.2012.555
P577
2012-04-19T00:00:00Z